Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ikervis Long-term Study in Dry Eye Disease With Severe Keratitis
NCT04144413Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of ciclosporin in dry eye disease (DED) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at 12 months. Started May 2019; status: completed.
02
Drugs
ciclosporin
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04144413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144413.